Freeline Therapeutics Holdings plc - ADR
FRLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.28M
Close$
Share Statistics
| Market cap | $28.28 Million |
|---|---|
| Enterprise Value | $9.95 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.52 |
| Beta | 0.66 |
| Outstanding Shares | 4,357,947 |
Return
| Return on Equity | -166.22% |
|---|---|
| Return on Assets | -101.45% |
| Return on Invested Capital | -225.13% |
Valuation & Multiples
| P/E Ratio | -0.29 |
|---|---|
| PEG | 1.53 |
| Price to Sales | - |
| Price to Book Ratio | 1.08 |
| Enterprise Value to Revenue | 16 |
| Enterprise Value to EBIT | -0.14 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.12 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Freeline Therapeutics Holdings plc
2,020 employeesFreeline Therapeutics Holdings PLC operates as a biotechnology company. The Company focuses on developing liver directed gene therapies for bleeding disorders and other debilitating chronic diseases. Freeline Therapeutics serves patients worldwide.